A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation

ID Number 16-1217

Principal Investigator(s)
Shyamala Navada

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to evaluate the safety and effectiveness of an investigational drug called ASP2215 in treatment for AML patients with mutations in FLT3 gene identified by an investigational FLT3 test using your blood or bone marrow to see if you have a mutations of the FLT3 gene, compared to salvage chemotherapy.

Contact Information
Rosalie Odchimar
(212) 824-7309

Recruiting Patients: Yes